BIOVIE INC. - COMMON STOCK

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

20 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

12 Jun 2024 07:24:05 By Nasdaq GlobeNewswire

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

04 Jun 2024 07:00:01 By Nasdaq GlobeNewswire

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

22 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie Inc. Announces Closing of Public Offering

06 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

BioVie Inc. Announces Pricing of Public Offering

04 Mar 2024 00:32:47 By Nasdaq GlobeNewswire

BioVie Inc. Announces Proposed Public Offering of Common Stoc

01 Mar 2024 15:58:24 By Nasdaq GlobeNewswire

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

13 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

BioVie to Participate in the Truist Securities BioPharma Symposium

02 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023

26 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

25 Oct 2023 11:30:41 By Nasdaq GlobeNewswire